Keystone Heart starts new trial of TriGUARD 3 cerebral embolic protection device
Medical devices maker Keystone Heart has started phase II of its Reflect trial assessing the safety and efficacy…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Jun 18
Medical devices maker Keystone Heart has started phase II of its Reflect trial assessing the safety and efficacy…
31 May 18
US-based Ancora Heart has raised $17.8m financing, which will be used to support clinical trials of its AccuCinch…
28 May 18
RenalGuard Solutions’s clinical trial showed that RenalGuard-guided diuretic therapy has improved breathing patterns and diuretic efficiency in acute…
26 May 18
Getinge said that its intra-aortic balloon pump (IABP) has shown positive results in a pilot study evaluating the…
25 May 18
The US Food and Drug Administration (FDA) has issued a Class I Recall of Abbott’s HeartMate 3 Left…
24 May 18
UK start-up Ultromics has secured £10m funding to advance the commercialization of artificial intelligence (AI) technology for the…
22 May 18
Cerenovus, part of the Johnson & Johnson Medical Devices Companies, has secured 510(k) clearance from the US Food…
17 May 18
Venus Medtech has secured equity investment from DCP Capital to speed up heart valve technology development and international…
17 May 18
Venus Medtech has secured equity investment from DCP Capital to speed up heart valve technology development and international…
15 May 18
Ancora Heart has expanded enrollment of US early feasibility study for the AccuCinch System for left ventricular repair.